|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6C
|
|
pubmed:dateCreated |
2003-1-29
|
|
pubmed:abstractText |
Liposomal formulations of the anthracyclines are being developed to circumvent toxicity and prolong effect. The current study investigates the in vitro activity of a novel doxorubicin micelle formulation, containing a vehicle designed to release pharmacologically active subcomponents.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4191-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12553055-Antineoplastic Agents,
pubmed-meshheading:12553055-Doxorubicin,
pubmed-meshheading:12553055-Drug Screening Assays, Antitumor,
pubmed-meshheading:12553055-Drug Synergism,
pubmed-meshheading:12553055-Ethanolamines,
pubmed-meshheading:12553055-Humans,
pubmed-meshheading:12553055-Micelles,
pubmed-meshheading:12553055-P-Glycoprotein,
pubmed-meshheading:12553055-Phosphotyrosine,
pubmed-meshheading:12553055-Tumor Cells, Cultured,
pubmed-meshheading:12553055-Tyrosine
|
|
pubmed:articleTitle |
Cytotoxic activity of a new lipid formulation of doxorubicin in cell lines and primary tumor cells.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology, Akademiska Hospital, Uppsala University, SE-751 85 Uppsala. Sweden.
|
|
pubmed:publicationType |
Journal Article
|
